

Bicycle Therapeutics presented data on zelenectide pevedotin, highlighting enhanced efficacy in cancer patients with NECTIN4 gene amplification.
You can purchase shares of Bicycle Therapeutics (NASDAQ:BCYC) through any online brokerage.
Other companies in Bicycle Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Bicycle Therapeutics has a consensus price target of $20.38.
The stock price for Bicycle Therapeutics (NASDAQ: BCYC) is $2.96 last updated November 20, 2026 at 8:12 AM EST.
There are no upcoming dividends for Bicycle Therapeutics.
Bicycle Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Bicycle Therapeutics.
Bicycle Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural...